Stryker Neurovascular, a division of Stryker, has released the results of its matrix and platinum science (MAPS) trial designed to treat both ruptured and unruptured aneurysms.
The MAPS trial is a prospective, randomized, controlled study designed to measure aneurysm treatment success, target aneurysm recurrence rate (TAR) using Matrix2 Detachable Coils or GDC Detachable Coils.
GDC Detachable Coils are made of very soft platinum wire and Matrix2 Detachable Coils consist of a PGLA polymer on the outside of a traditional platinum coil that is designed to degrade over time and promote rapid tissue development within the aneurysm.
GDC Detachable Coils are cleared by the FDA for the minimally invasive treatment of brain aneurysms in 1995.
Matrix2 Detachable Coils are cleared by the FDA 2002.
Stryker Neurovascular president Mark Paul said the MAPS Trial demonstrates the validity of TAR as a clinical endpoint and proves aneurysm coiling is an effective therapy with clinical outcomes.
"Stryker is encouraged by the results of the MAPS Trial, and we believe that it has the potential to influence the design of future studies and spur the advancement of new technologies that can enhance the clinical outcomes of patients with aneurysms in the future," Paul said.